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concurrently on an anticholinergic and a beta-3
agonist medication, respectively. 27 patients
reported significant bladder spasms and 24
reported concerns with urinary incontinence, prior
to undergoing BotA. 22 (81%) patients reported a
decrease in bladder spasms and 17 (71%)
reported a decrease in the amount of leakage per
urethra after BotA injections. 1 of 6 patients that
reported recurrent urinary tracts infections as a
problem reported a benefit. The average number
of BotA treatments was 3 per patient (range 1 to 8
treatments). All patients that reported benefit in
urinary symptoms were treated with 200 units of
BotA. There were no significant complications
reported.
Conclusion: Our results suggest that BotA may
be beneficial for treating bothersome urinary
symptoms, including incontinence and bladder
spasms, in patients with indwelling catheters. BotA
appears to be safe and well tolerated in this
patient population, consisting mainly of patients
with neurogenic conditions.
Funding: None.

Presented By: Keith Rohan Xavier, MD
Introduction: InterStim therapy is commercially
approved for the treatment of overactive bladder
(OAB) syndrome. The aim of this study was to
evaluate the performance and safety of the
recently updated and market-released InterStim

Basic Evaluation (BE) lead and foramen needles
in subjects undergoing a basic percutaneous
nerve evaluation for sacral neuromodulation.
Methods: Patients with OAB that were candidates
for InterStimTM therapy underwent a lead
placement and therapy evaluation. During lead
placement, sensory and motor data were collected
at both needle and lead placement. Subjects
completed urinary voiding diaries (3-6 days) to
assess change in lower urinary tract symptoms
from baseline. Safety was evaluated by the
collection of reportable adverse events.
Results:
Ninety-five (95) subjects with OAB had BE lead
implant procedure. The mean age was 63.5 ±
14.25, mean BMI 30.9 ± 8.12, and mean years
since OAB diagnosis was 9.2 ± 11.98. The
proportion of subjects that had motor or sensory
response at needle placement was 98.9% (94/95),
and the proportion with motor or sensory response
at lead placement was 96.8% (92/95). Seated
sensory response prior to discharge was obtained
in 100% (93/93) of subjects with successful lead
placements. Of the 89 subjects with one week
follow-up data, 88.8% (79/89) had a PGI-I
response of “Better”, 9% (8/89) had a response of
“No Change”, and 2.2% (2/89) had a response of
“Worse” with respect to their lower urinary tract
symptoms. There were no lead related AEs. Full
cohort final study results will be complete on
October 15, 2020 and will be available at the time
of presentation.
Conclusion: The recently-released BE lead and
foramen needles are safe and effective for therapy
evaluation in the setting of OAB. A high proportion
of patients maintained sensory response from
needle placement, through lead insertion, and at
time of lead removal. Final study results will be
provided at the time of presentation and will add to
the clinical evidence on the performance and
safety of the system.
Funding: Medtronic

Presented By: Andrea Pezzella, MD
Introduction: Sacral neuromodulation is a
guideline-recommended therapy for treatment of
urinary urgency incontinence (UUI) patients [1].
The Axonics® System is the first FDA-approved
rechargeable SNM system that is qualified to
delivery therapy for at least 15 years. The
ARTISAN-SNM study is a prospective, pivotal
study, designed to evaluate the safety and
effectiveness of the Axonics System for UUI
treatment. Clinical outcomes at 2 years are
presented.
Methods: 129 UUI participants across 19 centers
in the US and Europe were implanted with the
Axonics System in a single, non-staged
procedure. Clinical outcomes were reported from
3-day bladder diaries, a validated quality of life
questionnaire (ICIQ-OABqol), as well as
participant satisfaction and recharging
questionnaires. Therapy responders were defined
by a ≥50% reduction in UUI episodes per day
compared to baseline. As-treated and Completers
analyses were performed, with Completers as the
primary analysis method.

Results: Average participant age at baseline was
59.3 years (range: 21-86 years) and the average
body mass index (BMI) was 32 (range: 18-58).
Average baseline UUI episodes were 5.6 ± 0.3 per
day.
At 2 years, 93% of the participants were therapy
responders (Figure 1A). Of the responders, 82%
demonstrated a ≥75% reduction in UUI episodes
and 37% achieved full urinary continence.
Average UUI episodes per day reduced to 1.0 ±
0.2, an average reduction of 82% (p<0.0001; Fig
1B). Quality of life scores (ICIQ-OABqol) improved
by 36-points, which was clinically and statistically
significant (p<0.0001, 10-point improvement is
considered clinically significant).
All participants were able to recharge their device
and 94% of participants reported that the
recharging duration and frequency was
acceptable. There was no correlation between
participant demographic factors and clinical
outcomes or recharging experience. No serious or
unanticipated device-related adverse events were
reported throughout the study.
Conclusion: At 2 years, the Axonics System
demonstrated sustained safety and efficacy for
treatment of UUI, with significant improvements in
quality of life. Participant demographics were not
correlated with therapeutic or recharging
outcomes, indicating applicability of results to a
wide population.
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